tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Myelitis D009187 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Arm Injuries D001134 1 associated lipids
Intussusception D007443 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Oral Ulcer D019226 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Epididymitis D004823 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
Porokeratosis D017499 1 associated lipids
Lentigo D007911 1 associated lipids
Mutism D009155 1 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Akinetic Mutism D000405 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Orchitis D009920 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dysuria D053159 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Priapism D011317 1 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Lacerations D022125 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Scheel AK et al. Severe neurotoxicity of tacrolimus (FK506) after renal transplantation: two case reports. 2001 Nov-Dec Transplant. Proc. pmid:11750573
Woodle ES et al. Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group. 1998 Transplant. Proc. pmid:9636526
Barrera-Pulido L et al. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications. 2009 Jul-Aug Transplant. Proc. pmid:19715870
Burke GW et al. Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK 506 immunosuppression. 1998 Transplant. Proc. pmid:9532153
Sugioka A et al. FK 506 inhibits tolerance induction in mice liver transplantation. 2005 Jan-Feb Transplant. Proc. pmid:15808576
Büsing M et al. Mycophenolate mofetil/tacrolimus/single-shot versus azathioprine/cyclosporine/ATG in pancreas-kidney transplantation: results of a prospective randomized single-center study. 1998 Transplant. Proc. pmid:9532155
Tsang WK et al. Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients. 2000 Transplant. Proc. pmid:11119921
Gunji Y et al. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. 1993 Transplant. Proc. pmid:7679841
Murase N et al. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. 1990 Transplant. Proc. pmid:1689906
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Namii Y et al. Tetrahydropyranyladriamycin with FK 506 combination therapy for hamster-to-rat-concordant xenotransplantation. 1996 Transplant. Proc. pmid:8623358
Bond MMK et al. Cyclosporine Versus Tacrolimus: Which Calcineurin Inhibitor Has Influence on Cytomegalovirus Infection in Cardiac Transplantation? 2018 Transplant. Proc. pmid:29661443
Christians U et al. Interactions of FK 506 and cyclosporine metabolism. 1991 Transplant. Proc. pmid:1721280
Chan KL et al. Porcine small bowel transplantation with FK506 as a single immunosuppressant. 2001 Transplant. Proc. pmid:11406260
Platz KP et al. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. 1998 Transplant. Proc. pmid:9636596
Santos L et al. New-onset diabetes after transplantation: drug-related risk factors. 2012 Transplant. Proc. pmid:23146462
Ghobrial RM et al. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. 1998 Transplant. Proc. pmid:9636597
Kim SJ et al. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients. 2004 Transplant. Proc. pmid:15518759
Egawa H et al. Lymphoproliferative disorders in patients undergoing living-related liver transplantation. 1998 Transplant. Proc. pmid:9474982
Murata M et al. Unrelated donor bone marrow transplantation in Japanese patients is facilitated by the National Marrow Donor Program of the United States. 1998 Transplant. Proc. pmid:9474987
Ichimaru N et al. Risk factors and incidence for lipid abnormalities in kidney transplant patients. 2015 Transplant. Proc. pmid:25891708
Jain AB et al. One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. 1995 Transplant. Proc. pmid:7533353
Uchida H et al. Chronopharmacology of tacrolimus in rats: toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile. 1999 Transplant. Proc. pmid:10578276
Woo J et al. Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. 1991 Transplant. Proc. pmid:1721313
Masri M et al. Prograf five milligrams versus Tacrolimus medis in healthy volunteers: a bioequivalence study. 2013 Transplant. Proc. pmid:24314930
Laftavi MR et al. African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: does clotrimazole help? 2013 Transplant. Proc. pmid:24314941
Junge G et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. 2005 Transplant. Proc. pmid:15919434
Wilusz M et al. Effect of immunosuppressive therapy on the serum fatty acids of phospholipids fraction in patients after heart transplantation. 2014 Transplant. Proc. pmid:25380928
Huang CT et al. Higher Variability of Tacrolimus Trough Level Increases Risk of Acute Rejection in Kidney Transplant Recipients. Transplant. Proc. pmid:27569931
Kapturczak MH et al. Pharmacology of calcineurin antagonists. 2004 Transplant. Proc. pmid:15041303
Choi SJ et al. Tacrolimus-induced apoptotic signal transduction pathway. 2008 Transplant. Proc. pmid:18929848
Loh PT et al. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. 2008 Transplant. Proc. pmid:18589174
Hranjec T et al. Benign transient hyperphosphatasemia associated with Epstein-Barr virus enteritis in a pediatric liver transplant patient: a case report. 2008 Transplant. Proc. pmid:18589195
Takaori K et al. Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. 1992 Transplant. Proc. pmid:1376531
Kuroki H and Ikuta Y Nerve regeneration of vascularized rat limb allograft and functional recovery of long-term graft survivals treated by short course of FK 506 or cyclosporine. 1995 Transplant. Proc. pmid:7533405
Mieles LA et al. Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. 1991 Transplant. Proc. pmid:1721344
Tzakis AG et al. Campath-1H in intestinal and multivisceral transplantation: preliminary data. 2002 Transplant. Proc. pmid:12034248
Nakazato P et al. Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. 1991 Transplant. Proc. pmid:1721345
Junge G et al. Microchimerism in patients after orthotopic liver transplantation: a prognostic indicator? 2002 Transplant. Proc. pmid:12176475
Böttiger Y et al. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. 2002 Transplant. Proc. pmid:12176476
Kilian K et al. FK-506 (tacrolimus) therapy for an unusual SLE-like disease. 1998 Transplant. Proc. pmid:9865322
Schorlemmer HU and Kurrle R Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival. 1998 Transplant. Proc. pmid:9865337
Pohanka E et al. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients. 2005 Transplant. Proc. pmid:15919490
Marqués E et al. Development of lymphoproliferative disease after liver transplantation. 2008 Transplant. Proc. pmid:19010169
Perego C et al. Orthotopic liver-small bowel transplantation in pigs: study of immunologic parameters during therapy with FK 506-based immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907908
Alessiani M et al. Combined FK 506 and mycophenolate mofetil immunosuppression prolongs survival after small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907922
Boggi U et al. Neoral versus prograf in simultaneous pancreas-kidney transplantation with portal venous drainage: three-year results of a single-center, open-label, prospective, randomized pilot study. 2005 Jul-Aug Transplant. Proc. pmid:16182772
Hayakawa K et al. Involvement of clonal deletion in immunotolerance induction: tests of Tacrolimus administration in rat renal transplantation. 1994 Transplant. Proc. pmid:7520608
Kociszewska-Najman B et al. Congenital Infections in Neonates of Women With Liver or Kidney Transplants. 2016 Transplant. Proc. pmid:27496446
Yoshimura R et al. Study of the effect of immunosuppressive agents on renal cytochrome P-450 system in the rat. 1994 Transplant. Proc. pmid:7520610
Moreno JM et al. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. 2003 Transplant. Proc. pmid:12962831
Lieberman KV et al. FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). 1991 Transplant. Proc. pmid:1721376
Shapiro R et al. A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. 2002 Transplant. Proc. pmid:12176521
Demetris AJ et al. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703360
Nishimura Y et al. A trial to obtain donor-specific immunotolerance using a vascularized thymus allograft. 1998 Transplant. Proc. pmid:9838684
Damotte D et al. Morphologic features of large bowel biopsies in combined small and large bowel transplantations could predict clinical rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083252
Akutsu N et al. Two cases of calcineurin inhibitor-associated reversible posterior leukoencephalopathy syndrome in renal transplant recipients. 2008 Transplant. Proc. pmid:18790253
Ota H et al. Intrathymic microchimerism predicts rejection response in allograft recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123279
Cho JH et al. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. 2012 Transplant. Proc. pmid:22310591
Kiuchi T et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. 1996 Transplant. Proc. pmid:8962229
Ji SM et al. Conversion from cyclosporine to tacrolimus for chronic allograft nephropathy. 2007 Transplant. Proc. pmid:17580148
Arita S et al. Effect of FK 506 in experimental pancreas transplantation. 1995 Transplant. Proc. pmid:7536980
Bunnapradist S and Takemoto SK Controlling treatment allocation bias in a registry analysis when comparing calcineurin inhibitors. 2003 Transplant. Proc. pmid:14611971
Aono T et al. Minimal threshold of FK 506 for enhancing liver regeneration in thymectomized rats. 1995 Transplant. Proc. pmid:7536981
Balbontin FG et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. 2003 Transplant. Proc. pmid:14611982
Viebahn R et al. Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721401
Sato K et al. Effectiveness of triple drug immunosuppression for pancreaticoduodenal allotransplantation in dogs. 1992 Transplant. Proc. pmid:1379753
Masaki Y et al. Microchimerism and rat small bowel transplantation combined with donor-type bone marrow cells. 1996 Transplant. Proc. pmid:8769154
Morrisett JD et al. Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. 1991 Transplant. Proc. pmid:1721402
Kobayashi N et al. Abdominal organ cluster transplantation in pigs receiving FK 506. 1992 Transplant. Proc. pmid:1379754
Murphy MP and Morris RE Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. 1993 Transplant. Proc. pmid:7685955
Jordan ML et al. Tacrolimus rescue therapy for renal transplant rejection. 1996 Transplant. Proc. pmid:8769174
Langrehr JM et al. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563. 2001 Transplant. Proc. pmid:11377531
Tanabe K et al. Prospective analysis of thrombotic microangiopathy after renal transplantation: comparison between cyclosporine and tacrolimus immunosuppression. 2002 Transplant. Proc. pmid:12176590
Falconer SJ et al. Conversion from twice-daily to once-daily tacrolimus in simultaneous pancreas-kidney transplant patients. 2014 Transplant. Proc. pmid:24935313
Ishibashi M et al. Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max). 2001 Feb-Mar Transplant. Proc. pmid:11266958
Gibelli NE et al. Sirolimus in pediatric liver transplantation: a single-center experience. 2009 Transplant. Proc. pmid:19376384
Van Buren D et al. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients. 1998 Transplant. Proc. pmid:9723299
Kamar N et al. Efficacy and safety of induction therapy with rabbit antithymocyte globulins in liver transplantation for hepatitis C. 2004 Transplant. Proc. pmid:15621141
Sahara H et al. Thymectomy does not abrogate long-term acceptance of MHC class I-disparate lung allografts in miniature Swine. 2006 Transplant. Proc. pmid:17175240
El-Safa EA et al. Paradoxical response to tacrolimus assessed by interleukin-2 gene expression. 2006 Transplant. Proc. pmid:17175263
Moura Neto A et al. Frequency of Thyroid Dysfunction in Patients With Diabetes Mellitus Before and After Liver Transplantation. 2018 Transplant. Proc. pmid:29661439
Wu GD et al. FK 506 inhibits the development of transplant arteriosclerosis. 1991 Transplant. Proc. pmid:1721433
Makowka L et al. The effect of FK-506 on hyperacute rejection in presensitized rats. 1987 Transplant. Proc. pmid:2445082
Moreno M et al. Clinical management of tacrolimus drug interactions in renal transplant patients. 1999 Transplant. Proc. pmid:10500564
García Meseguer C et al. The effect of different immunosuppression on the outcome of pediatric renal transplants. 1999 Transplant. Proc. pmid:10500577
Tur MD et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. 2000 Transplant. Proc. pmid:11134804
Morena M et al. Low-density lipoprotein composition and oxidation are not influenced by calcineurin inhibitors in renal transplant patients. 2000 Transplant. Proc. pmid:11134805
Demir T et al. Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy. 2015 Transplant. Proc. pmid:26093731
Lee CM et al. Monotherapy with tacrolimus for heart and liver transplant: a case report. 2014 Transplant. Proc. pmid:24767396
Hesse CJ et al. Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. 2002 Transplant. Proc. pmid:12431679
Preston R et al. FK 506 as primary immunosuppressive therapy in renal transplantation. 1998 Transplant. Proc. pmid:9636493
Socci C et al. Pancreata from pediatric donors restore insulin independence in adult insulin-dependent diabetes mellitus recipients. 2010 Jul-Aug Transplant. Proc. pmid:20692410
Matsumoto S et al. ET-Kyoto ductal injection and density-adjusted purification combined with potent anti-inflammatory strategy facilitated single-donor islet transplantation: case reports. 2010 Jul-Aug Transplant. Proc. pmid:20692433
White SA et al. Effect of acute rejection on expression of fibrosis associated genes in renal transplant recipients. 2000 Transplant. Proc. pmid:10700949
Martins L et al. Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity? 2004 Transplant. Proc. pmid:15194300
Groth CG Immunosuppressive regimens of tomorrow. 1995 Transplant. Proc. pmid:8539797
Braun F et al. Living-related versus living-unrelated kidney transplantation using tacrolimus initial immunosuppression. 2000 Transplant. Proc. pmid:10700989
Finni PE et al. Is hepatitis C a risk factor to posttransplant diabetes mellitus after renal transplantation in patients using tacrolimus? 2004 Transplant. Proc. pmid:15194303
Jiang H et al. Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703702